HDAC9 and lung disorder: To date, reviews have been published devoted to either monotherapy of cancer, lung diseases (HDAC3), using HDAC inhibitors [34,35,36] and the effect of HDAC inhibitors on the immune system [37], or the antitumor activity of commercial chemotherapy drugs, for example, cisplatin and other platinum-based drugs [38,39].